Reproducibility of technetium-99m-MAG3 clearance using the Bubeck method.
The objective of this study was to estimate the reproducibility of 99mTc-mercaptoacetyltriglycine (99mTc-MAG3) clearance calculated using a single-sample method.


METHODS
One hundred forty-seven patients with urological or ear, nose and throat cancer were analyzed in a retrospective study. Each patient had at least two clearance studies with 99mTc-MAG3 before chemotherapy treatments to monitor renal function. Up to five clearance studies per patient were considered. The reproducibility was estimated by comparing two consecutive investigations. Pairs of investigations with a change in split renal function of more than 5% or an interval of more than 50 days were excluded. Clearance was determined using the Bubeck method. For each pair of consecutive clearance data, the difference between the first and the second measurements was expressed as a percentage of the mean value of the two measurements. The mean of these normalized differences represents the systematic deviation, and the s.d. represents the reproducibility of the compared clearances.


RESULTS
After the selection, 242 pairs of consecutive clearance data remained for comparison. Significantly different clearances were observed only between investigations 0 and 1 and between 4 and 5. The systematic deviation of these comparisons totaled -3.8% and -5.7%, respectively. In the other comparisons, no significant deviation induced by the chemotherapy was found. The reproducibility calculated for all comparisons totaled 11.7%.


CONCLUSIONS
The error of reproducibility of 99mTc-MAG3 clearance using the Bubeck method was < or =11.7%. This was an acceptable value, taking into account the greater fluctuation of tubular function compared with the glomerular filtration rate.
Werner
E
E
Clinic for Nuclear Medicine, University of Würzburg, Germany.
Blasl
C
C
Reiners
C
C
D006801:Humans; D007668:Kidney / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000503:physiopathology; D010039:Otorhinolaryngologic Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology; D011877:Radionuclide Imaging; D015203:Reproducibility of Results; D012189:Retrospective Studies; D017263:Technetium Tc 99m Mertiatide / Q000493:pharmacokinetics; D014565:Urogenital Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology
D017263:Technetium Tc 99m Mertiatide